Pathophysiology and multi-target prevention strategies for cyclophosphamide-induced bladder injury

Read full text Summarise with VIRAT
Authors: Xu Chang Liu, Jinxuan Li, Xujia Zhang, Xiong Yan, Pengyu Yan, Chun Liu
Cited by: 0
References: 99

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Cyclophosphamide (CYP) is a cornerstone alkylating agent in oncology, autoimmune diseases, and hematopoietic stem cell transplantation, but its clinical use is often limited by bladder toxicity. This toxicity is primarily caused by acrolein, a reactive CYP metabolite that accumulates in urine and initiates urothelial injury. Barrier disruption allows toxicants to penetrate, amplifying oxidative stress, inflammation, neurogenic inflammation, and sensory sensitization. Persistent or severe damage can lead to detrusor dysfunction, interstitial remodeling, fibrosis, and a range of conditions, including hemorrhagic cystitis, interstitial cystitis/bladder pain syndrome (IC/BPS)-like symptoms, overactive bladder, and reduced compliance. Emerging strategies are being explored, such as natural products targeting redox-inflammasome pathways, mechanism-driven small molecules, drug repurposing, regenerative and barrier-repair approaches, and metabolic interventions. A stage-oriented, target-matched combination paradigm supported by biomarker profiling may enhance bladder protection, but preserving antitumor efficacy and generating robust clinical evidence are key translational requirements.

Fields of Study & Subjects

Chemotherapy-induced organ toxicity mitigation Urinary Bladder and Prostate Research Bladder and Urothelial Cancer Treatments

Publication details

Journal / source
iScience
Volume
29
Issue
4
Pages
115512–115512
Publication date
28 March 2026
Language
EN